Parameters | Capecitabine | D1 | D2 | D3 | D4 |
---|---|---|---|---|---|
Blood brain barrier | + (0.6064) | + (0.5585) | + (0.5248) | + (0.5162) | + (0.5000) |
Human intestinal absorption | + (0.9513) | + (0.9569) | + (0.9524) | + (0.9322) | + (0.7879) |
P-glycoprotein inhibitor | Non-inhibitor (0.7514) | Non-inhibitor (0.6987) | Non-inhibitor (0.6305) | Non-inhibitor (0.5777) | Non-inhibitor (0.6890) |
CYP450 2C9 Inhibitor | Non-inhibitor (0.7673) | Non-inhibitor (0.7421) | Non-inhibitor (0.7490) | Non-inhibitor (0.7585) | Non-inhibitor (0.7696) |
Human ether-a-go–go-related (hERG) gene inhibition | Non-inhibitor (0.7124) | Non-inhibitor (0.6884) | Non-inhibitor (0.7261) | Non-inhibitor (0.7313) | Non-inhibitor (0.7409) |
Acute oral toxicity | III | III | III | III | III |
Rat acute toxicity, LD50 (mol/kg) | 2.4690 | 2.4907 | 2.4453 | 2.4229 | 2.4365 |
Ki at 298Â K (nM) | 3116.86 | 635.71 | 753.50 | 1242.24 | 1834.69 |